Table 3 Predictors of the rates of microbiologically documented sterile site infection clinically documented infection and fever of unknown origin per course among intensive treatment courses (N = 101)
Microbiological sterile site | Clinically documented | Fever of unknown origin | ||||
|---|---|---|---|---|---|---|
Rate ratio | P value | Rate ratio | P value | Rate ratio | P value | |
(CI) | (CI) | (CI) | ||||
Child characteristics at diagnosis | ||||||
Age in years | 0.92 | 0.082 | 0.99 | 0.748 | 0.92 | 0.025 |
(0.84, 1.01) | (0.92, 1.06) | (0.85, 0.99) | ||||
Obese vs. non-obese1 | 0.92 | 0.891 | 0.60 | 0.268 | 0.40 | 0.103 |
(0.29, 2.93) | (0.24, 1.48) | (0.13, 1.20) | ||||
Treatment characteristics | ||||||
APL-specific treatment protocol | 0.77 | 0.643 | 2.63 | 0.127 | 0.69 | 0.496 |
(0.25, 2.37) | (0.76, 9.10) | (0.24, 2.01) | ||||
Registered on study | 1.91 | 0.162 | 1.24 | 0.553 | 0.49 | 0.385 |
(0.77, 4.70) | (0.62, 2.48) | (0.10, 2.43) | ||||
Diagnosed prior to January 1, 2000 | 3.18 | 0.030 | 1.22 | 0.691 | 2.87 | 0.018 |
(1.12, 9.04) | (0.46, 3.18) | (1.20, 6.86) | ||||
Cumulative dose of cytarabine (g/m2) | 1.09 | 0.008 | 0.97 | 0.522 | 0.99 | 0.763 |
(1.02, 1.16) | (0.88, 1.07) | (0.90, 1.08) | ||||
Course characteristics | ||||||
Neutropenia (ANC <0.5 ×109) at start of course | 0.99 | 0.990 | 5.68 | <0.0001 | 1.36 | 0.436 |
(0.32, 3.06) | (2.42, 13.31) | (0.63, 2.93) | ||||
Greater than 15 days with neutropenia | 2.04 | 0.208 | 4.18 | 0.001 | 2.01 | 0.138 |
(0.67, 6.21) | (1.81, 9.62) | (0.80, 5.07) | ||||
Days receiving corticosteroids | 1.04 | 0.064 | 1.03 | 0.075 | 1.01 | 0.555 |
(1.00, 1.09) | (1.00, 1.07) | (0.97, 1.05) | ||||